You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 15, 2025

Histamine phosphate - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic sources for histamine phosphate and what is the scope of freedom to operate?

Histamine phosphate is the generic ingredient in one branded drug marketed by Lilly and is included in one NDA. Additional information is available in the individual branded drug profile pages.

Summary for histamine phosphate
US Patents:0
Tradenames:1
Applicants:1
NDAs:1
Raw Ingredient (Bulk) Api Vendors: 67
Clinical Trials: 1
Patent Applications: 640
What excipients (inactive ingredients) are in histamine phosphate?histamine phosphate excipients list
DailyMed Link:histamine phosphate at DailyMed
Recent Clinical Trials for histamine phosphate

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Kuopio University HospitalN/A

See all histamine phosphate clinical trials

Medical Subject Heading (MeSH) Categories for histamine phosphate
Anatomical Therapeutic Chemical (ATC) Classes for histamine phosphate

US Patents and Regulatory Information for histamine phosphate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Lilly HISTAMINE PHOSPHATE histamine phosphate INJECTABLE;INJECTION 000734-003 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Get Started Free ⤷  Get Started Free ⤷  Get Started Free
Lilly HISTAMINE PHOSPHATE histamine phosphate INJECTABLE;INJECTION 000734-001 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Get Started Free ⤷  Get Started Free ⤷  Get Started Free
Lilly HISTAMINE PHOSPHATE histamine phosphate INJECTABLE;INJECTION 000734-002 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Get Started Free ⤷  Get Started Free ⤷  Get Started Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Market Dynamics and Financial Trajectory for Histamine Phosphate

Last updated: July 30, 2025


Introduction

Histamine phosphate, a pharmaceutical compound utilized primarily for diagnostic and therapeutic purposes, occupies a niche yet critical role within the healthcare sector. Its utility spans allergy testing, gastric acid regulation, and as a research reagent, positioning it at the intersection of diagnostic innovation and pharmaceutical development. This analysis explores current market dynamics, growth drivers, challenges, and financial prospects associated with histamine phosphate, offering crucial insights for stakeholders and investors in the pharmaceutical landscape.


Market Overview and Segmentation

Histamine phosphate falls within the broader antihistamine and diagnostic agent market segment. Its primary applications include:

  • Diagnostic Use: Amplified in allergen testing, where it serves as an agent to evaluate hypersensitivity reactions.
  • Therapeutic Use: Historically used to stimulate gastric acid secretion in diagnostic procedures such as the H2 receptor antagonist testing.
  • Research & Development: Employed within biomedical research, especially in immunology and pharmacology.

The global market size remains modest relative to blockbuster drugs but demonstrates steady growth driven by increasing diagnostic procedures and ongoing research activities.


Market Dynamics

Growth Drivers

1. Rising Prevalence of Allergic Disorders

The global burden of allergies, including food allergies, allergic rhinitis, and atopic dermatitis, has surged over the past decade. According to the World Allergy Organization, approximately 30-35% of the global population suffers from allergic conditions, fueling demand for diagnostic agents like histamine phosphate [1].

2. Advancements in Diagnostic Technologies

Innovations in allergy testing, particularly in component-resolved diagnostics and broader immunological panels, elevate the use of substances such as histamine phosphate. These advancements offer precise allergy profiling, bolstering demand.

3. Growth in Biomedical Research

Increased investment in immunology and pharmacology research has expanded the use of histamine derivatives in experimental protocols. Government and private sector funding for allergy and gastric research supports sustained market activity.

4. Regulatory Approvals and Increased Clinical Adoption

Evolving regulatory landscapes favor standardization and approval of diagnostic agents, facilitating broader clinical acceptance. Agencies like the FDA endorse allergen testing protocols involving histamine phosphate, reinforcing its market position.


Challenges and Market Restraints

1. Decline in Therapeutic Usage

Once a mainstay for gastric testing, broader availability of more specific H2 receptor antagonists and proton pump inhibitors (PPIs) has reduced reliance on histamine phosphate therapeutically, limiting market growth.

2. Manufacturing and Supply Chain Concerns

The synthesis of histamine phosphate involves complex chemical processes, requiring high standards to prevent contamination. Regulatory compliance and supply chain disruptions could impact availability and pricing.

3. Market Fragmentation and Competition

Multiple companies produce histamine derivatives and alternative diagnostic agents, fostering a competitive environment that suppresses profit margins.

4. Regulatory Restrictiveness and Quality Concerns

Stringent manufacturing standards and the need for consistent quality control pose barriers, especially for smaller biotech firms or emerging market producers.


Financial Trajectory and Market Forecasts

Current Market Valuation

Based on recent industry reports, the global diagnostic agent market segment, including histamine phosphate, is valued at approximately $250-300 million in 2023. The therapeutic segment has shrunk notably, with revenues now accounting for a minor fraction of historical levels.

Projected Growth Rates

Analysts forecast a CAGR of 4-6% for the diagnostic segment over the next five years, driven by expanding allergy diagnostic services and ongoing research activities [2]. The research reagent market may grow at a faster pace, roughly 6-8% CAGR, reflecting increasing academic and industrial R&D investments.

Emerging Opportunities

  • Personalized Medicine: Integration of histamine testing into personalized allergy management strategies.
  • Biomarker Development: Potential use of histamine phosphate as a biomarker in immunotherapy efficacy.
  • Novel Formulations: Development of stable, standardized formulations for diagnostic consistency.

Risks and Financial Considerations

  • Market saturation in developed economies may limit revenue expansion.
  • Regulatory hurdles in emerging markets could delay product launches.
  • Price pressures from generic manufacturers could compress margins.

Competitive Landscape

Major players include pharmaceutical and biotech firms with established manufacturing capabilities:

  • Johnson & Johnson and Sanofi: Noted for diagnostic reagent portfolios.
  • Sigma-Aldrich (a Merck company): Supplies research-grade histamine compounds.
  • Fisher Scientific and Thermo Fisher: Distribute histamine phosphate for research use.

Smaller firms specializing in niche diagnostics continue to innovate, potentially disrupting traditional market shares.


Regulatory and Patent Considerations

While histamine phosphate itself is a long-established compound, ongoing patent protections for formulations or diagnostic kits involving histamine derivative innovations influence market exclusivity. Regulatory bodies, including the FDA and EMA, emphasize consistent manufacturing standards, impacting market entry and product development timelines.


Conclusion: Strategic Outlook

The market for histamine phosphate is characterized by steady, sustained demand primarily in diagnostics and research. While therapeutic applications have diminished, the compound's role in allergy testing and biomedical research ensures ongoing revenues. Stakeholders should focus on innovation in diagnostic kits, regulatory compliance, and expanding into emerging markets to maximize growth. Intellectual property protection focusing on formulations or novel deployment methods can offer competitive advantages.


Key Takeaways

  • Stable Demand Amid Industry Shifts: While therapeutic relevance declines, diagnostic and research applications maintain consistent demand.
  • Growth Driven by Allergy Diagnostics and Research: Increasing allergy prevalence and R&D investments bolster market prospects.
  • Challenges Include Market Fragmentation and Regulatory Barriers: Competition and compliance standards limit rapid expansion.
  • Investment Opportunities Lie in Diagnostic Innovation: Development of standardized, high-sensitivity kits and biomarker integration.
  • Market Stability Facilitates Moderate Growth: Forecasted CAGR of 4-6% reflects resilience despite challenges.

FAQs

1. What are the primary uses of histamine phosphate in healthcare today?
Histamine phosphate is mainly used for allergy testing, gastric acid secretion assessment, and as a research reagent in biomedical studies.

2. How is the demand for histamine phosphate expected to change in the next decade?
Demand is anticipated to grow steadily, driven by expanding allergy diagnoses and ongoing research activities, with an estimated CAGR of 4-6%.

3. What factors could impede the growth of histamine phosphate markets?
Regulatory restrictions, competition from alternative diagnostic agents, declining therapeutic use, and supply chain constraints pose risks.

4. Are there emerging markets for histamine phosphate?
Yes, regions such as Asia-Pacific and Latin America are expanding their diagnostic infrastructure, presenting growth opportunities for producers.

5. How does innovation influence the future trajectory of histamine phosphate?
Advancements in diagnostic kit standardization, integration into personalized medicine, and novel delivery methods will influence market expansion and financial returns.


References

[1] World Allergy Organization. (2022). Global allergy prevalence report.
[2] MarketsandMarkets. (2023). Diagnostic Reagents Market Forecast.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.